Page 6 - Clinj Am Soc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

United statesUnited kingdomJorge capapeyKim hollanderHyperoxaluria foundationGlobal rare disease lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean medicines agencyCommittee for medicinal products human usePrimary hyperoxaluria typeLower urinaryPlasma oxalate levelsAdult patients

Alnylam Pharma (ALNY) Announces FDA Approval of Supplemental New Drug Application for OXLUMO

Alnylam Pharma (ALNY) Announces FDA Approval of Supplemental New Drug Application for OXLUMO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine regan lindenboomJorge capapeyJosh brodskyKim hollanderHyperoxaluria foundationGlobal rare disease lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean medicines agencyCommittee for medicinal products human useNew drug applicationVice president

Race-free eGFR equation attenuates racial disparities in accrual of preemptive wait time

In a theoretical context, the 2021 creatine-based Chronic Kidney Disease Epidemiology Collaboration equation reduced racial differences in preemptive wait time accrual more than the use of the creatinine-cystatin equation, this study shows.Therefore, the race-free creatinine-based eGFR equation may reduce racial differences to preemptive wait time accrual, researchers wrote

United statesSan franciscoElaine kuJaymee lockeRhiannond reedUniversity of californiaHeersink school of medicineUniversity of alabama at birminghamChronic kidney disease epidemiology collaborationClinj am socChronic renal insufficiency cohortKidney disease epidemiology collaborationHeersink schoolComprehensive transplant institute

Kapruvia® approved in Switzerland with additional

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated.

United kingdomChristopher posnerIris francesconiThomas hutterKlaus henning jensenAnnie spinettaDrug administrationInternational journal of nephrologyRegulatory agencyExchange commissionCara therapeutics incAccess consortiumNational registry studyEuropean medicines agencyHealth canadaSwiss agency for therapeutic products swissmedic

Fresenius Medical Care North America Introduces First Single-Use Integrated Bloodline to Support Fluid Management in Dialysis

/PRNewswire/ Fresenius Medical Care North America s (FMCNA) Renal Therapies Group today announced the availability of the CombiSet SMARTECHTM, the first.

Scott sayresPat mccarthyOnline technologyExchange commissionTm blood chamberFresenius medical care ag coRenal therapies groupCorporate communicationsFresenius medical care holdings incLine blood chamberFresenius medical careOffers innovative new designFresenius medical care north americaMike angerChief medical officerMedical care north america